Q-omics provides the consensus-scored PLEKHG5 profile across patient tissues and cancer cell-line models. PLEKHG5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PLEKHG5 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PLEKHG5 RNA expression shows 18,844 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where PLEKHG5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHG5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHG5 survival associations across molecular data types. PLEKHG5 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHG5 RNA expression–survival associations across cancer types. High PLEKHG5 expression shows unfavorable associations in ACC, UVM, LUSC, THCA and BLCA, but favorable associations in LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify ACC as the clearest survival context for PLEKHG5 RNA expression.
This table summarizes PLEKHG5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLEKHG5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHG5 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, COAD, LIHC and THCA. The HNSC box plot shows higher PLEKHG5 RNA expression in tumor versus normal tissue (log2 FC = +1.081, t-test p < 0.001).
This table shows molecular features associated with PLEKHG5 in patient tissues and cancer cell lines. In patient samples, PLEKHG5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHG5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
